Real-world data, Covid-19 & biomarkers
- Real-world data, Covid-19 & biomarkers
- Meet-the-expert session – Patient profiling in HF: tailoring medical therapy (Supported by an educational grant funding from AstraZeneca)
- The new HF guidelines: diagnostic & treatment algorithms
- State of the art management of chronic HF
- Satellite symposium – Tailoring treatment to optimise care in HFrEF: The role of SGLT2 inhibitors (A symposium sponsored by the Boehringer Ingelheim & Lilly Alliance)
- Acute HF and the transition to ambulatory care
- Update on advanced HF, assist devices and heart transplantation
- Satellite symposium – Neuromodulation for the management of patients with HFrEF: the present and the future (Supported by an educational grant from CVRx)
- Difficult problems in HF
e-SPACE Heart Failure 2021 was the second edition of the annual global online conference on heart failure. Brining together leading experts from across the globe, the sessions were designed to provide insight and best demonstrate how leading experts are implementing the new heart failure guidelines into clinical practice. Discover the latest information on diagnosis and evidence-based management strategies from across the globe.
Heart failure is a major public health problem facing millions of patients worldwide. It represents an ever-increasing burden for healthcare systems, patients and healthcare professionals. Care for heart failure patients requires constant education and up-to-date information. The health outcomes of heart failure patients depend upon the implementation of best care approaches and evidence-based management strategies. e-SPACE Heart Failure 2021 strives to share the latest scientific information with the global medical community.
These on-demand recordings of the live virtual event (8 – 10 October 2021) comprise:
- Expert opinion and discussions from +40 international heart failure experts
- +10 sessions covering the latest HF scientific information and education
- Meet the Expert sessions and Symposia
More from this programme
Lars H Lund
Associate Professor and Senior Consultant
Dr Lund's expertise is in HF big data and registry-based comparative outcomes studies and pragmatic trials. He is active in programs to improve utilisation of existing evidence-based interventions in heart failure with reduced ejection fraction, as well as in novel interventions.
Dr Lars Lund is an Editorial Board member of Cardiac Failure Review.
James L Januzzi
Director of the Cardiac Intensive Care Unit
Dr James L Januzzi, is an Associate Professor of Medicine at Harvard Medical School and Director of the Cardiac Intensive Care Unit at Massachusetts General Hospital. He has an in-depht experience as a teacher and leads a research programme with specific focus on cardiac biomarker testing.
Dr Januzzi was the top-ranked graduate in his class at New York Medical College. He completed an internship and residency at Brigham and Women’s Hospital prior to performing a clinical and research fellowship in cardiovascular medicine at the Massachusetts General Hospital, where he also completed a fellowship in cardiac ultrasound.
He speaks widely on the topic of biomarker testing in heart disease and treatment of heart failure. He has served as the Cardiology Consultant to the Boston Red Sox since 2005.